iwewlkws Animal studies are critical for demonstrating the safety of a product prior to the initiation of human clinical trials. Clinical trials will not be allowed to proceed by the FDA if any major product-related safety issues are observed in animal studies. But did Elon Musk’s company get a break from this policy or lie to … Read more
Starting October 1, 2023, FDA no longer accepts paper 510k submissions. As announced before, 510k applications must be created using the eSTAR template and submitted electronically to the FDA for review. This week FDA released the final guidance for the electronic submission of 510k applications, confirming what it proposed about a year ago. Some important … Read more
For the last 15 years, the FDA’s attempts to regulate Lab Developed diagnostic Tests (LDTs) were rebuffed due to the lack of political will for such regulation or public support. FDA unsuccessfully tried to get Congress to pass new LDT laws, and its proposed guidance documents to regulate LDTs were derailed by strong opposition from … Read more
Cybersecurity requirements for FDA-regulated devices are evolving rapidly to stay in step with technological developments. This week the FDA released a detailed guidance document addressing several security issues around medical devices connected to the internet currently in development. The directions in this guidance document could append the ongoing development plans for internet-connected medical devices or … Read more
Meeting the FDA is unquestionably the most important resource available to sponsors/developers of new drugs and biologics. Over the last 30 years, these meetings have evolved into complex procedures. Their potential outcomes depend not on just what you ask but how you ask and when you ask the FDA about a particular issue related to … Read more
There have been numerous controversial decisions by the FDA in recent years where it approved new drugs despite its Advisory Committees (AdCom) recommending against it. But the FDA, being an equal opportunity disagreer, at times also rejects drugs that were recommended by its AdCom for approval as was shown this week when it rejected an … Read more
Although traditional FDA approval for a new drug or biologic requires evidence from two or more clinical trials, it is possible for the FDA to approve new products based on evidence from a single clinical trial under certain conditions. A new FDA Guidance Document released this week describes these conditions. The law provides the FDA … Read more
The FDA approval and the CDC endorsement of the latest Covid booster vaccines were received with a generally lukewarm reception. The CDC, FDA, and other government agencies presented the Covid booster vaccines as akin to the annual flu vaccine having followed a process to identify the prevailing strains of SARS-CoV-2 virus similar to that used … Read more
Emergency use or compassionate use protocols rely heavily on IRB review of such use of an investigational product. Individual patients in life-threatening conditions can be treated without prior approval by the FDA or an IRB with the expectation that the physician using an investigational treatment on his/her patient would inform the FDA and a relevant … Read more
The US FDA offers a grant of up to $3.6 million in non-dilutive funding to researchers developing new treatments for orphan drugs with an unmet medical need through a competitive selection process. Although the orphan drug development grant is not discussed much in funding circles, it offers several benefits, additional to the funds, to the … Read more
